The new weight-loss option will cut what ... year at current prices if every adult dealing with obesity took the drugs. Competition that drives down the cost of Wegovy and Zepbound could help ...

The announcement coincides with ... In February, Eli Lilly cut the monthly price for lower-dosage vials of its obesity drug Zepbound by $50 for consumers who pay cash via the drugmaker's ...

The Danish drugmaker Novo Nordisk announced it has temporarily reduced the price of the weight-loss ... compounded versions of the medication. The announcement coincides with a federal deadline ...

Much like the long-term users of its most popular product, Novo Nordisk's (NYSE: NVO) stock has slimmed down considerably of late. Share prices of the company, which developed and sells weight loss ...

The announcement coincides with a federal deadline on May 22, for manufacturers to cease distributing less expensive, compounded versions of the drug. Novo Nordisk officials said the one-time ...

The shares closed down nearly 12% after CVS Health's revelation and Lilly's announcement ... of Zepbound's arch rival Wegovy (semaglutide), sold by Novo Nordisk, after negotiating a price cut ...

Despite early success, however, Novo Nordisk has fallen behind in the GLP-1RA race, overtaken by Eli Lilly and its GLP-1RA asset tirzepatide, respectively sold under the brand names Zepbound and ...

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...